A population-based case-control teratologic study of furazidine, a nitrofuran-derivative treatment during pregnancy

A. E. Czeizel, M. Rockenbauer, H. T. Sørensen, J. Olsen

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective: To study human teratogenic potential of furazidine treatment during pregnancy. Design: Pair analysis of cases with congenital abnormalities and matched population controls. Setting: The Hungarian Case- Control Surveillance of Congenital Abnormalities. Participants: 38,151 pregnant women who had newborn infants without any defects (population control group) and 22.865 pregnant women who had newborns or fetuses with congenital abnormalities between 1980 and 1996. Results: In the case group, 157 (0.7%) and in the control group, 254 (0.7%) pregnant women were treated with furazidine. The case-control pair analysis did not indicate a teratogenic potential of furazidine use during the second to third months of gestation, i.e. in the critical period for major congenital abnormalities. Conclusion: Treatment with furazidine during pregnancy did not show teratogenic risk to the fetus.

Original languageEnglish
Pages (from-to)257-263
Number of pages7
JournalClinical Nephrology
Volume53
Issue number4
Publication statusPublished - Apr 26 2000

Keywords

  • Case-control analysis
  • Congenital abnormalities
  • Furazidine
  • Human teratogenic potential
  • Nitrofuran-derivatives

ASJC Scopus subject areas

  • Nephrology

Fingerprint Dive into the research topics of 'A population-based case-control teratologic study of furazidine, a nitrofuran-derivative treatment during pregnancy'. Together they form a unique fingerprint.

  • Cite this